{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-115151","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2026-10-13T10:01:28+00:00","discovered_at":"2026-10-13T10:05:00.580469+00:00","generated_at":"2026-10-13T10:05:54.629493+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.62,"calibrated_materiality_score":0.62,"confidence":"high","headline":"Zenas BioPharma reports Phase 3 INDIGO open-label extension obexelimab data in IgG4-RD","bullets":["12-month probability of remaining flare-free: 0.93 for adjudication committee-confirmed flares, 0.87 for investigator-determined; median cumulative glucocorticoid rescue dose 0 mg (mean 105 mg)","Obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference -11.4; p=0.021)","Vaccine sub-study: seroimmunity to influenza in 6 of 7 (86%) and COVID-19 in 4 of 4 (100%) during a treatment-free window averaging 34.6 days, with no disease flares","Participants (n=7) maintained pre-existing immunity markers after long-term obexelimab treatment: 71% for influenza and 50% for COVID-19","Data presented at the 6th International Symposium on IgG4-Related Disease, held October 8-10, 2026 in Cambridge, Massachusetts"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-115151","json":"https://secwatch.observer/filing/0001104659-26-115151.json","markdown":"https://secwatch.observer/filing/0001104659-26-115151.md","text":"https://secwatch.observer/filing/0001104659-26-115151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465926115151/0001104659-26-115151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465926115151/tm2627406d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T10:05:54.629493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}